Trial Profile
16 Weeks Interventional Study on Titration and Dose/Efficacy Assessment of Exelon (Rivastigmine) in Chinese Alzheimer's Disease Patients (INSTINCT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2017
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms INSTINCT
- Sponsors Novartis
- 30 Jun 2016 Status changed from recruiting to completed.
- 14 Apr 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov
- 14 Apr 2015 Planned primary completion date changed from 1 May 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov